+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Global Antifungal Agents Market 2021-2027

  • PDF Icon

    Report

  • August 2021
  • Region: Global
  • Orion Market Research Private Limited
  • ID: 5509803
UP TO OFF until Dec 31st 2022

Global Antifungal Agents Market Size, Share & Trends Analysis Report, By Drug Class (Polyene, Echinocandins, Allylamines, and Azole), By Dosage Type (Powder, Ointment, and Drugs), By Route of Administration (Parenteral, Topical, and Oral), Forecast Period 2021-2027


The global antifungal agents market is estimated to grow at a significant CAGR of nearly 3.5% during the forecast period. The rise in the prevalence of infections such as aspergillosis and candidiasis has been significantly driving the market. Another major factor propelling the growth of the market include the rise in incidences of fungal infection. As per the Centers for Disease Control and Prevention (CDC), in 2017, there were nearly 23,000 cases of invasive candidiasis in the US. 


Fungal diseases cost $7.2 billion in direct medical costs in 2017. 75,000 hospitalizations and nearly 9 million outpatient visits were reported due to fungal diseases in 2017. This, in turn, is encouraging the demand for antifungal agents that can fight fungal infection without damaging cells of the body. Furthermore, medical advancements that include ongoing drug discovery and public-private initiatives to treat fungal diseases are driving market growth. Additionally, evolving opportunities in emerging economies such as the development of advanced healthcare infrastructure facilities are also expected to propel the growth of the market. 


The COVID-19 pandemic has led to an increased demand for anti-fungal agents in the market. The patients hospitalized for the treatment of COVID-19 are at risk of healthcare-associated infections including candidemia or bloodstream infections that are caused by Candida. Additionally, the rise in the number of cases of black fungus, white fungus, and pink fungus has been increasing the demand for antifungal agents.


The global antifungal agents market is segmented based on drug class, dosage type, and route of administration. Based on drug class, it is segmented into polyene, echinocandins, allylamines, azole. Based on dosage type, it is further classified into powder, ointment, and drugs.  Based on the route of administration, it is further classified into parenteral, topical, and oral.  


Geographically, the market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America is anticipated to witness a significant share in the market owing to the potential healthcare spending and rising prevalence of fungal diseases in the region. Furthermore, specialized drug discovery for these diseases in the region also drives the market growth in the North American market. In addition, the presence of established pharmaceutical companies, which are consistently focusing on extensive commercialization of their drugs and enhancing their geographical reach, is anticipated to be a key factor escalating the growth of the market in the region. 


Whereas, Asia-Pacific is expected to be the fastest-growing region in the market. The attributable factors include improving healthcare infrastructure, rising incidences of black fungus and other fungi in the country such as India, and rising medical tourism in the region. Thus, the global players are focusing on high R&D investment as well as commercializing branded drugs at a relatively lower price in the region. 


Major players in the market include Abbott Laboratories, Inc., Pfizer Inc., and Bayer AG, among others. Partnership & collaborations, product launches, and mergers and acquisitions are some crucial strategies adopted by the market players to gain a competitive advantage over their competitors.


Research Methodology

The market study of the global antifungal agents market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to break down the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.


Secondary Sources Include

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.


Market Segmentation

  1. Global Antifungal Agents Market Research and Analysis, By Drug Class
  2. Global Antifungal Agents Market Research and Analysis, By Dosage Type
  3. Global Antifungal Agents Market Research and Analysis, By Route of Administration

The Report Covers

  • Comprehensive research methodology of the global antifungal agents market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global antifungal agents market.
  • Insights about market determinants that are stimulating the global antifungal agents market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players

Table of Contents

1. Report Summary
  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Antifungal Agents Industry
  • Recovery Scenario of Global Antifungal Agents Industry
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. BY Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Key Strategy Analysis
3.3. Impact of COVID-19 on Key Players
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Global Antifungal Agents Market, by Drug Class
5.1.1. Polyene
5.1.2. Echinocandins
5.1.3. Allylamines
5.1.4. Azole
5.2. Global Antifungal Agents Market, by Dosage Type
5.2.1. Powder
5.2.2. Ointment
5.2.3. Drugs
5.3. Global Antifungal Agents Market, by Route of Administration
5.3.1. Parenteral
5.3.2. Topical
5.3.3. Oral
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. South Korea
6.3.5. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. Abbott Laboratories, Inc.
7.2. Astellas Pharma Inc.
7.3. Basilea Pharmaceutica Ltd.
7.4. Bayer Healthcare LLC
7.5. Bristol-Myers Squibb Co.
7.6. Cadila Healthcare Ltd.
7.7. Cosmo Pharmaceuticals N.V.
7.8. Dr. Reddy’s Laboratories Ltd.
7.9. Gilead Sciences, Inc.
7.10. Janssen Pharmaceutica NV
7.11. Mayne Pharma Group Ltd.
7.12. Merck & Co., Inc.
7.13. Pfizer Inc.
7.14. Sanofi-Aventis Groupe SA
7.15. SCYNEXIS, Inc.
7.16. Sumitomo Dainippon Pharma Co., Ltd.
7.17. Sun Pharmaceutical Industries Ltd.
7.18. Teva Pharmaceutical Industries Ltd.
7.19. Viatris Inc.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Abbott Laboratories, Inc.
  • Astellas Pharma Inc.
  • Basilea Pharmaceutica Ltd.
  • Bayer Healthcare LLC
  • Bristol-Myers Squibb Co.
  • Cadila Healthcare Ltd.
  • Cosmo Pharmaceuticals N.V.
  • Dr. Reddy’s Laboratories Ltd.
  • Gilead Sciences, Inc.
  • Janssen Pharmaceutica NV
  • Mayne Pharma Group Ltd.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sanofi-Aventis Groupe SA
  • SCYNEXIS, Inc.
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.